Innate Pharma (IPHA) Return on Capital Employed (2021 - 2025)
Innate Pharma (IPHA) reported Return on Capital Employed of 377.03% for Q4 2025, down 28618.0% on a YoY basis from N/an in Q4 2024, and down 138.41% quarter-over-quarter from 158.15% in Q2 2025.
Innate Pharma (IPHA) Return on Capital Employed (2021 - 2025) Analysis & Trends
Innate Pharma has reported Return on Capital Employed for 5 years, with the latest figure at 377.03% in Q4 2025.
- For the quarter ending Q4 2025, Return on Capital Employed fell 28618.0% year-over-year to 377.03%; the trailing twelve-month figure through Dec 2025 stood at 377.03% (down 28618.0% YoY), and the FY2025 full-year result was 118.21%, down 7164.0% from the prior year.
- Return on Capital Employed for Q4 2025 stood at 377.03%, down from 158.15% in the prior quarter.
- The five-year high for Return on Capital Employed was 13.42% in Q2 2021, with the low at 377.03% in Q4 2025.
- Historically, Return on Capital Employed has averaged 88.06% across 5 years, with a median of 29.49% in 2021.
- Annual changes were most pronounced in 2022 — Return on Capital Employed surged 311 bps — and 2025, when it tumbled 28618 bps.
- Innate Pharma's Return on Capital Employed stood at 29.49% in 2021, then gained by 11 bps to 26.37% in 2022, then tumbled by 55 bps to 40.84% in 2023, then plunged by 122 bps to 90.85% in 2024, then plunged by 315 bps to 377.03% in 2025.
- The last three Return on Capital Employed figures came in at 377.03% (Q4 2025), 158.15% (Q2 2025), and 90.85% (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -107.40% |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -50.43% |
| 10 | Innate Pharma | 194.19 Mn | 194.19 Mn | - | -377.03% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -377.03% |
| Jun 30, 2025 | -158.15% |
| Dec 31, 2024 | -90.85% |
| Jun 30, 2024 | -28.93% |
| Dec 31, 2023 | -40.84% |
| Jun 30, 2023 | -27.50% |
| Dec 31, 2022 | -26.37% |
| Dec 31, 2021 | -29.49% |
| Jun 30, 2021 | -13.42% |